Dr. Peter L. Jones leads a research lab at the University of Nevada Reno focused on developing innovative therapies for Facioscapulohumeral muscular dystrophy (FSHD) using CRISPR technology. Their work aims to repress the harmful gene DUX4 in muscle cells to alleviate symptoms of this genetic disorder. The lab's efforts include the design of advanced delivery systems for CRISPR components in muscle tissue and testing these in mouse models to establish effective treatment strategies.

Dr. Kevin D. Wickman's lab studies how certain proteins in the brain help control the signals that influence mood and behavior. They focus on understanding the mechanisms by which G protein-coupled receptors, specifically GABAB receptors, regulate brain cell signaling. By using advanced techniques, they aim to uncover new ways to treat neurological disorders that result from dysfunctional signaling pathways.

Dr. Danica Galonic Fujimori's lab focuses on understanding how certain bacteria develop resistance to antibiotics through modifications to their ribosomes. This research is important because it helps us combat the growing problem of antibiotic resistance, which affects public health and treatment options. The lab uses advanced techniques to study the enzymes involved in this process and aims to uncover new strategies to tackle bacterial infections.

Dr. Chen Gao's lab focuses on understanding how the degradation of RNA molecules influences the development of heart diseases, particularly heart hypertrophy. By studying the mechanisms of mRNA stability and degradation in heart cells, the lab aims to uncover new potential targets for treating cardiovascular diseases. Their research combines advanced sequencing technologies with mouse models to explore gene regulation in response to stress and other physiological changes.

Dr. Angie Gelli's lab at the University of California, Davis focuses on developing new antifungal treatments to combat serious fungal infections that threaten human health. Using innovative techniques, the lab aims to create and optimize antifungal peptides that can effectively target and destroy fungi while being safe for human cells. The research is critical as we face rising drug resistance in fungal pathogens and aims to create compounds that can save lives.

Dr. Howard E. Gendelman's research lab focuses on innovative approaches to combat HIV through targeted therapies. They are developing lipid nanoparticles that can deliver gene therapies specifically to HIV-infected cells, aiming to eliminate hidden viral reservoirs. The lab also investigates the effects of HIV on neurodegenerative diseases, particularly Alzheimer's, using specially designed animal models to understand the interplay between viral infection and brain health.

Dr. Danzhou Yang's lab at Purdue University focuses on developing innovative therapies for cancer and inflammatory diseases. The lab investigates the regulation of gene expression, specifically targeting a unique structure in DNA known as a G-quadruplex to suppress the overexpression of a protein called PDGFR-beta, which is implicated in various diseases. By designing and synthesizing small molecular compounds that interact with this structure, the lab aims to create more effective treatments for conditions where PDGFR-beta is a key player.

Dr. Paul B. Watkins' lab at the University of North Carolina Chapel Hill focuses on understanding how genetic differences influence the effectiveness and safety of adeno-associated virus (AAV) gene therapies, particularly related to liver toxicity. By studying a diverse population of genetically different mice, the lab aims to uncover the underlying genetic factors that contribute to variability in how patients respond to AAV treatments. This research is intended to improve the design of safer and more effective gene therapies for genetic disorders that require liver targeting.

Dr. Kathleen Giacomini's lab at UCSF focuses on studying membrane transporters, which are crucial for moving drugs, nutrients, and other substances across cell membranes, especially in the brain. The lab seeks to understand how these transporters work in the blood-brain barrier, a critical site that regulates what enters the brain. By using cutting-edge methods like structural biology and computational modeling, the team aims to identify potential new treatments and improve our understanding of drug delivery in the brain.

Dr. Vanessa H. Routh's lab studies the effects of low blood sugar in people with diabetes, particularly how the brain senses these dangerous drops. They use innovative animal models to examine the roles of certain neurons in this process and the potential of the drug modafinil to restore awareness of hypoglycemia. This research is crucial for developing better treatments for diabetic patients who suffer from dangerous hypoglycemia without realizing it.

Dr. Stephen Traynelis's lab at Emory University focuses on understanding how glutamate receptors function in the brain and their role in neurological diseases. The team employs advanced techniques like electrophysiology and cryo-electron microscopy to explore how genetic variations in these receptors can affect synaptic function and contribute to disorders like Alzheimer's and Parkinson's disease. By developing new therapeutic compounds, they aim to improve treatments and identify precision medicine strategies for brain-related conditions.

Yale E. Goldman's lab at UC Davis focuses on understanding how molecular motors and ribosomes function in cells. They study the dynamics of these cellular machines, which are crucial for protein synthesis and transport within cells, using cutting-edge biophysical techniques. Their research aims to uncover mechanisms that contribute to diseases like muscular dystrophy and cystic fibrosis, with the goal of identifying potential therapeutic strategies.

Dr. Santhi Gorantla's lab at the University of Nebraska Medical Center focuses on understanding how HIV-1 persists in the central nervous system and how it can be attacked using new therapies. The lab studies immune cells that harbor the virus, particularly in the brain, to find out how drug use affects HIV's presence and the development of related neurological disorders. By using a specially developed mouse model that mimics human biology, the lab aims to develop strategies to eliminate HIV-1 from these reservoirs and improve treatment outcomes for patients.

Dr. Sachin A. Gupte's research lab focuses on understanding how metabolic changes, particularly involving a protein called glucose-6-phosphate dehydrogenase (G6PD), can influence vascular diseases. By studying how different forms of G6PD might affect blood vessel cells, the lab aims to uncover new mechanisms that could lead to better treatments for conditions like heart disease and artery stiffness, which are significant health issues worldwide.

Dr. Chenthamarakshan Vasu's lab focuses on understanding how the gut microbiota and its metabolites influence autoimmune diseases and gut health. They study the effects of beta-glucans, a type of dietary fiber, on the gut microbiome and aim to identify novel metabolites produced during its degradation that could have therapeutic benefits. This research may lead to innovative nutrition and medicine strategies to prevent and treat immune-related disorders.

Dr. Jorge Silvio Gutkind's lab at UC San Diego focuses on improving treatments for head and neck cancer, a disease that currently has low survival rates and limited responses to conventional therapies. The lab is investigating how disruptions in certain cellular signaling pathways contribute to cancer progression and immune evasion. They are also exploring innovative approaches using chemokines to enhance the effectiveness of immunotherapies, aiming to make treatments more successful for patients.

Dr. Klaus M. Hahn's lab focuses on understanding how cells communicate and behave by developing advanced imaging techniques to visualize and control protein activity in real time. They study the dynamics of signaling in various contexts, like immune cells and cancer progression, to uncover fundamental principles of cell biology. The aim is to create tools that can help researchers explore diverse biological questions, especially related to how cells react to their environment.

The lab of Dr. Mark T Hamann focuses on the synthesis and optimization of unique natural products called aleutianamines, derived from deep-sea marine organisms. The research aims to develop effective methods for creating these alkaloids, which have potential therapeutic applications for diseases like malaria and cancer. By exploring innovative synthesis techniques, the lab seeks to address the scarcity of these natural compounds and harness their medicinal properties.

Dr. Osama F Harraz's lab at the University of Vermont focuses on understanding how blood flow to the brain is regulated and how that process is affected in conditions like hypertension. They study a protein called Piezo1, which acts as a sensor in blood vessel cells, enabling them to respond to changes in blood flow. By examining how this protein functions in different scenarios, the lab aims to identify new strategies for treating cardiovascular diseases that impact brain health.

Dr. Thurl E. Harris's lab at the University of Virginia focuses on understanding how our body manages energy, particularly during the process of eating and fasting. The lab studies how different types of adenosine receptors in our fat tissues respond to food intake and how these responses can become dysfunctional in obesity. By exploring these mechanisms, the research aims to uncover better ways to manage conditions like obesity and insulin resistance.